Can you provide the last earnings date for PHARMING GROUP NV - ADR?
PHARMING GROUP NV - ADR (PHAR) last reported earnings on 3/12/2026.
PHARMING GROUP NV - ADR (PHAR) Earnings History & Surprises
NASDAQ:PHAR • US71716E1055
Current stock price
17.13 USD
-0.44 (-2.5%)
Last:
PHAR Earnings overview
Past quarterly earnings results for PHARMING GROUP NV - ADR (PHAR), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.07
- Revenue Estimate
- 96.563M
Last Reported
Most Recent- Release Date
- Mar 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.08
- EPS Surprise
- -6.76%
- Revenue Surprise
- -1.68%
Beat Rate
Last 8 Quarters 44%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.08 | 0.09 | -6.76% | 60.00% | 106.533M | 108.35M | -1.68% | 14.96% |
| Q3 2025 | 0.10 | -0.01 | 1,070.87% | 600.00% | 97.3M | 96.233M | 1.11% | 30.00% |
| Q2 2025 | 0.06 | -0.26 | 123.30% | 400.00% | 93.2M | 85.758M | 8.68% | 25.79% |
| Q1 2025 | -0.22 | -0.15 | -42.39% | -15.79% | 79.094M | 69.767M | 13.37% | 42.29% |
| Q4 2024 | 0.05 | 0.07 | -27.22% | 225.00% | 92.672M | 83.166M | 11.43% | 14.10% |
| Q3 2024 | -0.02 | -0.03 | 22.33% | -140.00% | 74.849M | 79.238M | -5.54% | 12.28% |
| Q2 2024 | -0.02 | 0.08 | -124.27% | - | 74.093M | 76.668M | -3.36% | 34.97% |
| Q1 2024 | -0.19 | 0.07 | -363.52% | -11.76% | 55.586M | 70.478M | -21.13% | 30.66% |
| Q4 2023 | -0.04 | 0.10 | -138.83% | 80.00% | 81.217M | 74.933M | 8.39% | 48.69% |
| Q3 2023 | 0.05 | -0.27 | 118.67% | -61.54% | 66.661M | 63.18M | 5.51% | 22.90% |
| Q2 2023 | 0.00 | -0.12 | 100.00% | -100.00% | 54.897M | 54.363M | 0.98% | 9.47% |
| Q1 2023 | -0.17 | -0.07 | -153.92% | -421.07% | 42.541M | 49.595M | -14.22% | -8.74% |
| Q4 2022 | -0.20 | 0.06 | -430.23% | - | 54.621M | 61.724M | -11.51% | -72.53% |
| Q3 2022 | 0.13 | 0.00 | - | 1,201.69% | 54.238M | 55.62M | -2.48% | 2.60% |
| Q2 2022 | 0.04 | 0.10 | -61.66% | -66.78% | 50.146M | 53.198M | -5.74% | 0.95% |
| Q1 2022 | 0.05 | - | -60.04% | 46.617M | - | 18.92% | ||
| Q4 2021 | 0.00 | 0.00 | - | -100.00% | 198.871M | 57.508M | 245.81% | -6.27% |
| Q3 2021 | -0.01 | 0.00 | - | -110.09% | 52.864M | 55.686M | -5.07% | 14.62% |
| Q2 2021 | 0.12 | 0.17 | -30.05% | -21.87% | 49.673M | 69.371M | -28.40% | 26.40% |
| Q1 2021 | 0.13 | 0.14 | -7.25% | 9.23% | 39.199M | 63.237M | -38.01% | -20.48% |
| Q4 2020 | 0.15 | 0.09 | 76.63% | - | 212.174M | 62.49M | 239.53% | - |
| Q3 2020 | 0.12 | 0.19 | -40.11% | - | 46.121M | 56.991M | -19.07% | - |
| Q2 2020 | 0.15 | 0.15 | 2.61% | - | 39.299M | 59.743M | -34.22% | - |
| Q1 2020 | 0.12 | 0.20 | -38.37% | - | 49.294M | 54.624M | -9.76% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
286.26%
Max EPS beat (4)
1,070.87%
Min EPS beat (4)
-42.39%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
5.37%
Max Revenue beat (4)
13.37%
Min Revenue beat (4)
-1.68%
Analysis
In the last 4 quarters, PHAR has beaten EPS estimates in 2 out of 4 releases
PHAR has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, PHAR has beaten the EPS estimates by 286.3% on average.
In the last 4 quarters, PHAR has beaten the revenue estimates by 5.4% on average.
Related analysis
PHARMING GROUP NV - ADR / PHAR Earnings FAQ
Can you provide information on whether PHARMING GROUP NV - ADR beat earnings estimates in the last quarter?
PHARMING GROUP NV - ADR (PHAR) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does PHAR stock beat earnings estimates?
In the last 4 quarters, PHARMING GROUP NV - ADR (PHAR) has beaten EPS estimates in 2 out of 4 releases.